Skip to main content
Biohit Oyj logo

Biohit Oyj — Investor Relations & Filings

Ticker · BIOBV ISIN · FI0009005482 LEI · 74370089ATTSNBXJVT29 HE Manufacturing
Open in API
Filings indexed 992 across all filing types
Latest filing 2023-02-15 Earnings Release
Country FI Finland
Listing HE BIOBV

About Biohit Oyj

https://www.biohithealthcare.com/en/

Biohit Oyj is a global biotechnology company that develops, manufactures, and markets innovative diagnostic products and services. The company specializes in tools for the early diagnosis and prevention of diseases, with a primary focus on gastroenterology. Its key offerings include the GastroPanel® blood test for assessing stomach health and screening for risks of gastric cancer, as well as diagnostic tests for conditions such as Helicobacter pylori infection. Operating under the mission "Innovating for Health," Biohit's products are designed to support medical research, facilitate early and accurate diagnosis, and improve patient quality of life.

Recent filings

Filing Released Lang Actions
BIOHIT-KONSERNIN TILINPÄÄTÖSTIEDOTE 2022
Earnings Release Classification · 98% confidence The document is a 'Tilinpäätöstiedote' (Financial Statements Release) for the year 2022, published by Biohit Oyj on February 15, 2023. It contains comprehensive financial highlights, management commentary, key performance indicators (KPIs), and a summary of the fiscal year's performance. While it is a release, it serves as the primary annual financial disclosure document for the company, which aligns with the definition of an Earnings Release (ER) or a preliminary annual report. Given the detailed nature of the financial tables and management discussion, it is classified as an Earnings Release. FY 2022
2023-02-15 Finnish
BIOHIT-KONSERNIN TILINPÄÄTÖSTIEDOTE 2022
Earnings Release Classification · 98% confidence The document is titled "BIOHIT-KONSERNIN TILINPÄÄTÖSTIEDOTE 2022" (Biohit Group Financial Statement Release 2022) and is dated February 15, 2023. It contains a comprehensive summary of financial results for the full year (Tammi-joulukuu 2022) and the second half of the year, including detailed tables for revenue, profit/loss, balance sheet items, and management commentary on performance and outlook. This structure, covering a full fiscal year with detailed financial figures and management discussion, strongly indicates a comprehensive annual financial report release. Although it is a 'Tiedote' (Release), its content depth (47k characters, detailed tables, MD&A section) surpasses a simple Earnings Release (ER) or a Report Publication Announcement (RPA). In the context of the provided definitions, this is the primary document summarizing the full year's performance, aligning best with the scope of an Annual Report (10-K), even if it is a local equivalent release rather than the specific SEC form. Given the comprehensive nature covering the entire fiscal year, '10-K' is the most appropriate classification for a full-year financial report summary. FY 2022
2023-02-15 Finnish
BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2022
Audit Report / Information Classification · 98% confidence The document is titled "BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2022" and contains detailed financial figures for the period January-December 2022, including revenue, EBITDA, operating profit, balance sheet items, and key figures tables comparing 2022 results to 2021. It also includes a CEO's review and outlook. This content structure is characteristic of a comprehensive financial report covering a full fiscal year, which aligns with the definition of an Annual Report (10-K). However, the document is explicitly labeled a 'Financial Statement Release' and is relatively concise compared to a full 10-K filing, often serving as the initial public release of the annual results before the full statutory filing. Given the options, this is the most comprehensive annual financial disclosure provided, making it closest to an Annual Report (10-K) or potentially an Interim/Quarterly Report (IR) if it were for a shorter period. Since it covers the full year (January-December 2022) and presents the final audited/reviewed figures, it functions as the primary annual financial disclosure. If this were a US filer, it would be the basis for the 10-K. For non-US filers, this detailed annual release is often classified as the closest equivalent to the Annual Report or a very detailed Interim Report. Since it covers the full year and is a 'Release', it is most accurately classified as an Earnings Release (ER) or a detailed Interim Report (IR) if the company structure implies this is the main annual filing. Given the depth of the financial tables and the CEO review, it surpasses a typical 'Earnings Release' (ER) which is usually just highlights. It is more comprehensive than a standard quarterly report (IR) because it covers the full year. In many contexts, a detailed annual financial statement release is treated as the Annual Report (10-K) equivalent for classification purposes, but since the definition for 10-K is 'Official yearly report covering company activity and full financial performance,' and this is a 'Release,' I must consider the possibility of it being an Earnings Release (ER) or a detailed Interim Report (IR). Since it covers the full year, it is the annual result. The presence of the CEO's review and detailed segment data suggests it is more than just the initial highlights (ER). It is the comprehensive annual financial disclosure. I will classify it as the closest equivalent to the Annual Report (10-K) based on the period covered (full year) and the level of detail, despite the 'Release' nomenclature, as it contains the full annual performance summary. If the document were significantly shorter and only announced the release of the full report, it would be RPA. Since it contains the data itself, 10-K is the best fit for a full-year financial disclosure. FY 2022
2023-02-15 English
12152667.pdf
Board/Management Information Classification · 100% confidence The document is a short announcement regarding a change in the company's senior management (specifically the departure of the R&D Director and the appointment of a successor). This fits the definition of a management change announcement.
2022-12-15 Finnish
Muutos Biohitin johtoryhmässä: tuotekehitysjohtaja vaihtuu
Board/Management Information Classification · 100% confidence The document is a short announcement regarding a change in the company's management team (specifically the departure of the R&D Director and the appointment of a successor). This fits the definition of a management/board change announcement.
2022-12-15 Finnish
Muutos Biohitin johtoryhmässä: tuotekehitysjohtaja vaihtuu
Board/Management Information Classification · 99% confidence The document is a short announcement dated 15.12.2022 regarding a change in senior management at Biohit Oyj. Specifically, it states that the Chief Development Officer (tuotekehitysjohtaja) has resigned and another executive will take over the responsibilities. This directly matches the definition for Board/Management Information (MANG), which covers announcements of changes in senior management.
2022-12-15 Finnish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.